HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy.

Abstract
An imbalance in oxidative stress and antioxidant defense mechanisms contributes to the development of ischaemic retinopathies such as diabetic retinopathy and retinopathy of prematurity (ROP). Currently, the therapeutic utility of targeting key transcription factors to restore this imbalance remains to be determined. We postulated that dh404, an activator of nuclear factor erythroid-2 related factor 2 (Nrf2), the master regulator of oxidative stress responses, would attenuate retinal vasculopathy by mechanisms involving protection against oxidative stress-mediated damage to glia. Oxygen-induced retinopathy (OIR) was induced in neonatal C57BL/6J mice by exposure to hyperoxia (phase I) followed by room air (phase II). dh404 (1 mg/kg/every second day) reduced the vaso-obliteration of phase I OIR and neovascularization, vascular leakage and inflammation of phase II OIR. In phase I, the astrocytic template and vascular endothelial growth factor (VEGF) expression necessary for physiological angiogenesis are compromised resulting in vaso-obliteration. These events were attenuated by dh404 and related to dh404's ability to reduce the hyperoxia-induced increase in reactive oxygen species (ROS) and markers of cell damage as well as boost the Nrf2-responsive antioxidants in cultured astrocytes. In phase II, neovascularization and vascular leakage occurs following gliosis of Müller cells and their subsequent increased production of angiogenic factors. dh404 reduced Müller cell gliosis and vascular leakage in OIR as well as the hypoxia-induced increase in ROS and angiogenic factors with a concomitant increase in Nrf2-responsive antioxidants in cultured Müller cells. In conclusion, agents such as dh404 that reduce oxidative stress and promote antioxidant capacity offer a novel approach to lessen the vascular and glial cell damage that occurs in ischaemic retinopathies.
AuthorsDevy Deliyanti, Jae Young Lee, Steven Petratos, Colin J Meyer, Keith W Ward, Jennifer L Wilkinson-Berka, Judy B de Haan
JournalClinical science (London, England : 1979) (Clin Sci (Lond)) Vol. 130 Issue 15 Pg. 1375-87 (08 01 2016) ISSN: 1470-8736 [Electronic] England
PMID27005782 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society.
Chemical References
  • Angiogenic Proteins
  • Antioxidants
  • Cytokines
  • Inflammation Mediators
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, mouse
  • Nfe2l2 protein, rat
  • dh404 compound
  • Oleanolic Acid
Topics
  • Angiogenic Proteins (metabolism)
  • Animals
  • Animals, Newborn
  • Antioxidants (pharmacology)
  • Astrocytes (drug effects, metabolism, pathology)
  • Capillary Permeability (drug effects)
  • Cells, Cultured
  • Cytokines (metabolism)
  • Disease Models, Animal
  • Ependymoglial Cells (drug effects, metabolism, pathology)
  • Hyperoxia (complications)
  • Inflammation Mediators (metabolism)
  • Mice, Inbred C57BL
  • NF-E2-Related Factor 2 (agonists, metabolism)
  • Oleanolic Acid (analogs & derivatives, pharmacology)
  • Oxidative Stress (drug effects)
  • Rats, Sprague-Dawley
  • Retina (drug effects, metabolism, pathology)
  • Retinal Neovascularization (etiology, metabolism, pathology, prevention & control)
  • Retinopathy of Prematurity (etiology, metabolism, pathology, prevention & control)
  • Signal Transduction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: